Your browser is no longer supported. Please, upgrade your browser.
Settings
ZLAB [NASD]
Zai Lab Limited
Index- P/E- EPS (ttm)-5.57 Insider Own0.20% Shs Outstand95.03M Perf Week1.78%
Market Cap6.74B Forward P/E- EPS next Y-4.08 Insider Trans-71.22% Shs Float87.94M Perf Month-20.35%
Income- PEG- EPS next Q0.04 Inst Own69.50% Short Float3.29% Perf Quarter-52.88%
Sales86.78M P/S77.67 EPS this Y-14.20% Inst Trans3.54% Short Ratio4.91 Perf Half Y-58.87%
Book/sh16.71 P/B4.22 EPS next Y37.60% ROA- Target Price196.69 Perf Year-34.30%
Cash/sh16.40 P/C4.30 EPS next 5Y- ROE- 52W Range60.57 - 193.54 Perf YTD-47.92%
Dividend- P/FCF- EPS past 5Y-56.80% ROI-25.80% 52W High-63.58% Beta1.24
Dividend %- Quick Ratio14.30 Sales past 5Y- Gross Margin- 52W Low16.36% ATR5.19
Employees692 Current Ratio14.50 Sales Q/Q124.50% Oper. Margin- RSI (14)35.49 Volatility8.78% 6.56%
OptionableYes Debt/Eq0.00 EPS Q/Q41.80% Profit Margin- Rel Volume0.75 Prev Close64.04
ShortableYes LT Debt/Eq0.00 EarningsNov 09 AMC Payout- Avg Volume588.99K Price70.48
Recom1.60 SMA20-10.89% SMA50-24.45% SMA200-48.40% Volume444,531 Change10.06%
Oct-12-21Initiated Bernstein Mkt Perform
Apr-28-20Initiated Goldman Buy
Apr-15-20Initiated Guggenheim Buy $75
Jul-12-19Initiated BofA/Merrill Buy
Jul-05-19Initiated Macquarie Outperform
Jan-29-19Initiated Credit Suisse Outperform
Nov-21-18Initiated Jefferies Buy
Jun-21-18Resumed Leerink Partners Outperform $43
Feb-14-18Upgrade JP Morgan Neutral → Overweight
Oct-16-17Initiated Leerink Partners Outperform $42
Oct-16-17Initiated JP Morgan Neutral $32
Dec-03-21 07:30AM  
Nov-30-21 07:30AM  
Nov-23-21 07:30AM  
Nov-22-21 07:30AM  
Nov-20-21 11:17AM  
Nov-16-21 07:30AM  
Nov-15-21 07:30AM  
Nov-12-21 08:46AM  
Nov-11-21 07:30AM  
Nov-09-21 04:10PM  
08:00AM  
08:00AM  
07:37AM  
07:00AM  
Nov-08-21 12:44PM  
Nov-04-21 07:30AM  
Nov-03-21 11:05AM  
Oct-28-21 06:31PM  
Oct-26-21 07:30AM  
Oct-25-21 07:30AM  
Oct-21-21 06:11AM  
03:00AM  
Oct-20-21 04:05PM  
10:36AM  
Oct-19-21 09:00AM  
Oct-18-21 07:30AM  
Oct-15-21 10:27AM  
Oct-11-21 11:08PM  
07:30AM  
Oct-04-21 01:06PM  
09:10AM  
07:30AM  
Sep-22-21 12:22PM  
Sep-20-21 03:22PM  
Sep-17-21 10:25AM  
Sep-16-21 07:30AM  
Sep-14-21 07:30AM  
Sep-10-21 05:06PM  
Sep-09-21 07:30AM  
Aug-25-21 08:30AM  
Aug-24-21 07:30AM  
Aug-09-21 04:30PM  
Aug-04-21 11:53AM  
10:57AM  
07:30AM  
Jul-27-21 08:00AM  
Jul-22-21 07:30AM  
Jul-06-21 09:38AM  
Jun-20-21 04:53AM  
Jun-16-21 08:27AM  
07:30AM  
Jun-08-21 10:48AM  
Jun-01-21 07:30AM  
07:30AM  
May-28-21 07:30AM  
May-25-21 07:30AM  
May-24-21 09:21AM  
May-14-21 12:58PM  
May-10-21 07:32AM  
May-05-21 04:05PM  
07:30AM  
Apr-26-21 07:30AM  
Apr-23-21 10:49AM  
Apr-21-21 10:49AM  
Apr-20-21 07:40PM  
07:28AM  
Apr-19-21 04:05PM  
Apr-14-21 11:44AM  
Apr-13-21 07:37AM  
Apr-06-21 11:46AM  
Mar-31-21 04:57AM  
Mar-12-21 11:54AM  
Mar-04-21 04:19PM  
Mar-02-21 11:56PM  
Mar-01-21 07:00AM  
Feb-27-21 09:23AM  
Feb-18-21 07:31AM  
Jan-28-21 07:30AM  
Jan-11-21 06:45AM  
04:30AM  
Jan-06-21 04:01PM  
Dec-30-20 07:30AM  
06:05AM  
Dec-29-20 08:09AM  
Dec-28-20 07:00PM  
07:30AM  
Dec-16-20 08:15PM  
Dec-01-20 07:30AM  
Nov-11-20 08:30AM  
Nov-10-20 07:00PM  
Oct-29-20 07:30AM  
Oct-28-20 03:18PM  
07:30AM  
Oct-09-20 08:48AM  
Oct-06-20 07:30AM  
Oct-05-20 07:30AM  
Sep-28-20 08:35PM  
07:30AM  
Sep-27-20 11:26PM  
11:21PM  
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, and infectious diseases primarily in Greater China. The company's commercial products include Zejula for the treatment of breast cancer and non-small cell lung cancer; Optune, a device that delivers tumor treating fields; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other lymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naive- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; TPX-0022, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin-17; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. It has development, license, and collaboration agreements with GlaxoSmithKline; Paratek Bermuda, Ltd.; Five Prime Therapeutics, Inc.; Entasis Therapeutics Holdings, Inc.; Crescendo Biologics Ltd.; Novocure Limited; MacroGenics Inc.; Deciphera Pharmaceuticals, LLC; Incyte Corporation; Regeneron Ireland Designated Activity Company; Turning Point Therapeutics Inc; Cullinan Pearl Corp.; Takeda Pharmaceutical Company Limited; Schrodinger, Inc.; and argenx BV. The company was incorporated in 2013 and is headquartered in Shanghai, China.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DIEKMAN JOHN DDirectorNov 05Sale91.651,00091,65060,852Nov 08 04:23 PM
Fu TaoPresident & COOOct 28Sale105.0010,0001,049,97877,500Oct 29 05:15 PM
Fu TaoPresident & COOOct 14Sale102.6810,0001,026,79987,500Oct 14 08:40 PM
Fu TaoPresident & COOSep 30Sale106.7310,0001,067,33597,500Oct 01 05:37 PM
Fu TaoPresident & COOSep 15Option Exercise18.9210,000189,200217,500Sep 16 09:59 PM
Fu TaoPresident & COOSep 15Sale134.0910013,409207,500Sep 27 05:58 PM
Fu TaoPresident & COOSep 15Sale127.869,9001,265,778207,600Sep 16 09:59 PM
Reinhart HaraldChief Medical OfficerSep 09Option Exercise3.0010,00030,00010,000Sep 10 04:17 PM
Reinhart HaraldChief Medical OfficerSep 09Sale141.3610,0001,413,6210Sep 10 04:17 PM
Reinhart HaraldChief Medical OfficerSep 07Option Exercise3.0010,00030,00010,000Sep 08 09:02 PM
Du YingChairwoman & CEOSep 07Sale150.7329,7854,489,5231,008,653Sep 08 08:48 PM
Reinhart HaraldChief Medical OfficerSep 07Sale150.9310,0001,509,2590Sep 08 09:02 PM
Du YingChairwoman & CEOSep 03Sale145.0424,1453,501,9401,038,438Sep 03 06:43 PM
Du YingChairwoman & CEOSep 02Sale145.7928,7384,189,6101,062,583Sep 03 06:43 PM
Du YingChairwoman & CEOSep 01Option Exercise0.60111,11166,6671,119,764Sep 03 06:43 PM
Du YingChairwoman & CEOSep 01Sale146.4628,4434,165,6961,091,321Sep 03 06:43 PM
Fu TaoPresident & COOAug 25Option Exercise18.9210,000189,200217,000Aug 26 07:12 PM
Fu TaoPresident & COOAug 25Sale143.0310,0001,430,285207,000Aug 26 07:12 PM
Reinhart HaraldChief Medical OfficerAug 24Option Exercise17.998,000143,9208,000Aug 25 05:47 PM
Reinhart HaraldChief Medical OfficerAug 24Sale143.368,0001,146,8800Aug 25 05:47 PM
Reinhart HaraldChief Medical OfficerAug 23Option Exercise17.998,000143,9208,000Aug 25 05:47 PM
Reinhart HaraldChief Medical OfficerAug 23Sale135.008,0001,080,0000Aug 25 05:47 PM
DIEKMAN JOHN DDirectorAug 05Sale149.501,000149,50061,852Aug 05 06:57 PM
Du YingChairwoman & CEOAug 03Sale146.3826,2173,837,7591,008,653Aug 03 08:15 PM
Du YingChairwoman & CEOAug 02Option Exercise0.60111,11166,6671,116,649Aug 03 08:15 PM
Du YingChairwoman & CEOAug 02Sale144.5684,89412,272,2561,034,870Aug 03 08:15 PM
Fu TaoPresident & COOJul 15Option Exercise18.9210,000189,200217,000Jul 19 06:02 PM
Fu TaoPresident & COOJul 15Sale172.8210,0001,728,189207,000Jul 19 06:02 PM
Reinhart HaraldChief Medical OfficerJul 14Option Exercise18.008,000143,9604,000Jul 15 08:05 PM
Reinhart HaraldChief Medical OfficerJul 14Sale169.118,0001,352,8800Jul 15 08:05 PM
Reinhart HaraldChief Medical OfficerJul 13Option Exercise18.008,000144,0008,000Jul 15 08:05 PM
Reinhart HaraldChief Medical OfficerJul 13Sale169.928,0001,359,3600Jul 15 08:05 PM
Du YingChairwoman & CEOJul 02Sale175.3127,2534,777,6591,008,653Jul 02 06:02 PM
Du YingChairwoman & CEOJul 01Option Exercise0.60111,11166,6671,119,764Jul 02 06:02 PM
Du YingChairwoman & CEOJul 01Sale175.7083,85814,734,0901,035,906Jul 02 06:02 PM
Reinhart HaraldChief Medical OfficerJun 17Option Exercise18.008,000144,0008,000Jun 17 08:04 PM
Reinhart HaraldChief Medical OfficerJun 17Sale161.648,0001,293,1200Jun 17 08:04 PM
Reinhart HaraldChief Medical OfficerJun 16Option Exercise20.908,000167,2008,000Jun 17 08:04 PM
Reinhart HaraldChief Medical OfficerJun 16Sale162.718,0001,301,6800Jun 17 08:04 PM
Fu TaoPresident & COOJun 15Option Exercise18.9210,000189,200217,000Jun 17 08:01 PM
Fu TaoPresident & COOJun 15Sale165.2810,0001,652,786207,000Jun 17 08:01 PM
Cho William Ki ChulChief Financial OfficerJun 02Sale180.691,416255,85750,000Jun 02 09:02 PM
Du YingChairwoman & CEOJun 02Sale177.529,4631,679,8471,008,653Jun 02 09:00 PM
Du YingChairwoman & CEOJun 01Option Exercise0.60111,11166,6671,119,764Jun 02 09:00 PM
Cho William Ki ChulChief Financial OfficerJun 01Sale180.128,5841,546,15051,416Jun 02 09:02 PM
Du YingChairwoman & CEOJun 01Sale176.19101,64817,909,4041,018,116Jun 02 09:00 PM
Fu TaoPresident & COOMay 26Option Exercise18.9210,000189,200217,000May 26 08:20 PM
Fu TaoPresident & COOMay 26Sale159.4010,0001,594,036207,000May 26 08:20 PM
Reinhart HaraldChief Medical OfficerMay 25Option Exercise20.908,000167,2008,000May 26 08:18 PM
Reinhart HaraldChief Medical OfficerMay 25Sale161.668,0001,293,2800May 26 08:18 PM
Reinhart HaraldChief Medical OfficerMay 24Option Exercise20.908,000167,2008,000May 26 08:18 PM
Reinhart HaraldChief Medical OfficerMay 24Sale162.378,0001,298,9600May 26 08:18 PM
DIEKMAN JOHN DDirectorMay 05Sale153.621,000153,62062,852May 06 07:49 PM
Du YingChairwoman & CEOMay 04Sale158.1148,9477,738,927786,430May 04 08:37 PM
Du YingChairwoman & CEOMay 03Sale161.5762,16410,044,049835,377May 04 08:37 PM
Reinhart HaraldChief Medical OfficerApr 21Option Exercise20.908,000167,2008,000Apr 21 07:59 PM
Reinhart HaraldChief Medical OfficerApr 21Sale161.998,0001,295,9200Apr 21 07:59 PM
Reinhart HaraldChief Medical OfficerApr 20Option Exercise20.908,000167,2008,000Apr 21 07:59 PM
Reinhart HaraldChief Medical OfficerApr 20Sale150.208,0001,201,6000Apr 21 07:59 PM
Fu TaoPresident & COOApr 19Option Exercise18.9210,000189,200217,000Apr 21 08:01 PM
Fu TaoPresident & COOApr 19Sale162.9110,0001,629,140207,000Apr 21 08:01 PM
Du YingChairwoman & CEOApr 07Sale134.4221,9362,948,655897,541Apr 07 07:55 PM
Du YingChairwoman & CEOApr 06Sale127.2838,3924,886,566919,477Apr 07 07:55 PM
Du YingChairwoman & CEOApr 05Sale126.1950,7846,408,461957,869Apr 07 07:55 PM
Fu TaoPresident & COOMar 26Option Exercise18.9220,000378,400207,000Mar 30 06:48 PM
Chen Kai-XianDirectorMar 12Sale142.534,302613,16424,662Mar 30 08:51 PM